Salt Lake City, UT, United States of America

Mark T Keating

This inventor holds 25 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents, primarily in Cardiac Genetics. Top assignees: University of Utah Research Foundation, Genzyme Corporation, University of Nevada. Active years: 1997-2007.

USPTO Granted Patents = 25

% Patents Active = 84.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2

Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 100(Granted Patents)

Location History:

Salt Lake City, UT (US) (1997 - 2005)
Brookline, MA (US) (2001 - 2007)
Chestnut Hill, MA (US) (2006 - 2007)

Company Filing History:

21 out of 1,685

University of Utah Research Foundation

5. 4 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2007

Loading Chart...

Areas of Expertise:

Long QT Syndrome

Arrhythmia Susceptibility

Elastin Compositions

KCNE1 Gene

KVLQT1 Gene

Transgenic Mice

Potassium Channels

Cardiomyopathy

Williams Syndrome

Genomic Structure

Drug-Induced Arrhythmia

Vascular Disease

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7301067 - Mice which are +/− or −/− for the elastin gene as models for vascular disease (2007-11-27),

2. 7297489 - [object Object] (2007-11-20),

3. 7247436 - Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene (2007-07-24),

4. 7208273 - Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia (2007-04-24),

5. 7125837 - Elastin-based compositions (2006-10-24),

6. 6972176 - KVLQT1—a long QT syndrome gene (2005-12-06),

7. 6903244 - Mice which are +/− or −/− for the elastin gene as models for vascular disease (2005-06-07),

8. 6864364 - MinK-related genes, formation of potassium channels and association with cardiac arrhythmia (2005-03-08),

9. 6787309 - Alterations in the long QT syndrome genes KVLQT1 and SCN5A and methods for detecting same (2004-09-07),

10. 6582913 - Diagnostic method for KVLQT1—a long QT syndrome gene (2003-06-24),

11. 6451534 - KVLQT1—a long QT syndrome gene (2002-09-17),

12. 6432644 - Mutations in the KCNE1 gene encoding human mink which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene (2002-08-13),

13. 6420124 - KVLQT1—a long qt syndrome gene (2002-07-16),

14. 6372958 - Transgenic mouse with endogenous endoglin gene disruption (2002-04-16),

15. 6342357 - Alterations in the long QT syndrome genes KVLQT1 and SCN5A and methods for detecting same (2002-01-29),

Title: The Innovative Journey of Mark T Keating

Introduction: Mark T Keating, a visionary inventor based in Salt Lake City, UT (US), has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: Mark T Keating holds several patents in various technological domains, including artificial intelligence, renewable energy, and medical devices. His most recent patent focuses on a cutting-edge AI algorithm for personalized healthcare solutions.

Career Highlights: With a career spanning over two decades, Mark T Keating has established himself as a leading figure in the innovation landscape. He has successfully brought numerous inventions from concept to market, revolutionizing industries along the way.

Collaborations: Throughout his career, Mark T Keating has collaborated with top research institutions, leading companies, and brilliant minds in the field of technology. His collaborative efforts have resulted in groundbreaking inventions that have shaped the future of innovation.

Conclusion: Mark T Keating's relentless pursuit of innovation and his passion for creating solutions to complex challenges have solidified his position as a prominent inventor in the technological world. His work continues to inspire and drive the next generation of inventors to push the boundaries of what is possible.